Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 418

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 418
---
5

    George Ng

    /s/ Robert Hoffman
     
    Director
     
    March 31, 2025

    Robert Hoffman /s/ Craig Tendler______________________Craig Tendler, M.D.
     
      Director
     
      March 31, 2025  

119

INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS

TuHURA Biosciences, Inc. and Subsidiaries

    Report of Independent Registered Public Accounting Firm (PCAOB ID No. 677)
    F-3

    Consolidated Balance Sheets as of December 31, 2024 and 2023
    F-5

    Consolidated Statements of Operations for the years ended December 31, 2024 and 2023
    F-6

    Consolidated Statements of Stockholders’ Equity (Deficit) for the years ended December 31, 2024 and 2023
    F-7

    Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023
    F-9

    Notes to the Consolidated Financial Statements
    F-10

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and the Board of Directors

TuHURA Biosciences, Inc.

Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of TuHURA Biosciences, Inc. (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations, stockholders’ (deficit) equity, and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively the “financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

The Company’s Ability to Continue as a Going Concern 

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has recurring losses and negative cash flows from operations that raise substantial doubt about its ability to continue as a going concern. Management’s plans regarding those matters are also described in Note